Literature DB >> 35299751

Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Sajad Fakhri1, Seyed Zachariah Moradi1,2, Akram Yarmohammadi3, Fatemeh Narimani3, Carly E Wallace4, Anupam Bishayee4.   

Abstract

Background: Tumors often progress to a more aggressive phenotype to resist drugs. Multiple dysregulated pathways are behind this tumor behavior which is known as cancer chemoresistance. Thus, there is an emerging need to discover pivotal signaling pathways involved in the resistance to chemotherapeutic agents and cancer immunotherapy. Reports indicate the critical role of the toll-like receptor (TLR)/nuclear factor-κB (NF-κB)/Nod-like receptor pyrin domain-containing (NLRP) pathway in cancer initiation, progression, and development. Therefore, targeting TLR/NF-κB/NLRP signaling is a promising strategy to augment cancer chemotherapy and immunotherapy and to combat chemoresistance. Considering the potential of phytochemicals in the regulation of multiple dysregulated pathways during cancer initiation, promotion, and progression, such compounds could be suitable candidates against cancer chemoresistance.
Objectives: This is the first comprehensive and systematic review regarding the role of phytochemicals in the mitigation of chemoresistance by regulating the TLR/NF-κB/NLRP signaling pathway in chemotherapy and immunotherapy.
Methods: A comprehensive and systematic review was designed based on Web of Science, PubMed, Scopus, and Cochrane electronic databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed to include papers on TLR/NF-κB/NLRP and chemotherapy/immunotherapy/chemoresistance by phytochemicals.
Results: Phytochemicals are promising multi-targeting candidates against the TLR/NF-κB/NLRP signaling pathway and interconnected mediators. Employing phenolic compounds, alkaloids, terpenoids, and sulfur compounds could be a promising strategy for managing cancer chemoresistance through the modulation of the TLR/NF-κB/NLRP signaling pathway. Novel delivery systems of phytochemicals in cancer chemotherapy/immunotherapy are also highlighted.
Conclusion: Targeting TLR/NF-κB/NLRP signaling with bioactive phytocompounds reverses chemoresistance and improves the outcome for chemotherapy and immunotherapy in both preclinical and clinical stages.
Copyright © 2022 Fakhri, Moradi, Yarmohammadi, Narimani, Wallace and Bishayee.

Entities:  

Keywords:  NF-κB – nuclear factor-kappa B; NLRP; TLR - toll-like receptor; chemotherapy; immunotherapy; molecular pharmacology; phytochemicals; signaling pathways

Year:  2022        PMID: 35299751      PMCID: PMC8921560          DOI: 10.3389/fonc.2022.834072

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  477 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro.

Authors:  Patrick Mannal; Debbie McDonald; David McFadden
Journal:  Am J Surg       Date:  2010-11       Impact factor: 2.565

3.  Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.

Authors:  Hai Huang; Qiong Wang; Tao Du; Chunhao Lin; Yiming Lai; Dingjun Zhu; Wanhua Wu; Xiaoming Ma; Soumin Bai; Zean Li; Leyuan Liu; Qi Li
Journal:  Prostate       Date:  2018-01-21       Impact factor: 4.104

4.  Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways.

Authors:  Bilal Bin Hafeez; Mohammad Sarwar Jamal; Joseph W Fischer; Ala Mustafa; Ajit Kumar Verma
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

5.  Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway.

Authors:  Suat Erdogan; Kader Turkekul; Ilker Dibirdik; Oguzhan Doganlar; Zeynep B Doganlar; Ayhan Bilir; Gulperi Oktem
Journal:  Biomed Pharmacother       Date:  2018-08-22       Impact factor: 6.529

6.  Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.

Authors:  Sabita N Saldanha; Rishabh Kala; Trygve O Tollefsbol
Journal:  Exp Cell Res       Date:  2014-02-08       Impact factor: 3.905

7.  Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel.

Authors:  Sun Mi Kim; So Yong Lee; Dong Yeon Yuk; Dong Cheul Moon; Sang Sook Choi; Youngsoo Kim; Sang Bae Han; Ki-Wan Oh; Jin Tae Hong
Journal:  Arch Pharm Res       Date:  2009-05-27       Impact factor: 4.946

8.  Inhibitory effect of phytoglycoprotein on tumor necrosis factor-alpha and interleukin-6 at initiation stage of colon cancer in 1,2-dimethylhydrazine-treated ICR mice.

Authors:  Sei-Jung Lee; Kye-Taek Lim
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-02       Impact factor: 4.219

9.  Evolution of platinum resistance in high-grade serous ovarian cancer.

Authors:  Susanna L Cooke; James D Brenton
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

10.  Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines.

Authors:  Chariya Hahnvajanawong; Wareeporn Wattanawongdon; Chariya Chomvarin; Natthinee Anantachoke; Sakawrat Kanthawong; Banchob Sripa; Vichai Reutrakul
Journal:  Cancer Cell Int       Date:  2014-10-24       Impact factor: 5.722

View more
  1 in total

Review 1.  Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.

Authors:  Devesh Tewari; Anu Priya; Anusha Bishayee; Anupam Bishayee
Journal:  Clin Transl Med       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.